Astrana Health (ASTH) EBIT (2010 - 2026)

Astrana Health (ASTH) has 17 years of EBIT data on file, last reported at $28.5 million in Q1 2026.

• Quarterly EBIT rose 38.6% year-over-year to $28.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (down 79.62% YoY) and the FY2025 annual result came in at $8.3 million, down 90.69% from the prior year.
• EBIT advanced to $28.5 million in Q1 2026 per ASTH's latest filing, from -$51.8 million in the prior quarter.
• The five-year high for EBIT was $50.1 million in Q3 2022, with the low at -$51.8 million in Q4 2025.
• Average EBIT over 5 years is $18.5 million, with a median of $22.4 million recorded in 2023.
• Year-over-year, EBIT surged 459.61% in 2022 and tumbled 7296.39% in 2025.
• Astrana Health's EBIT stood at $12.6 million in 2022, then tumbled by 130.76% to -$3.9 million in 2023, then surged by 118.6% to $720000.0 in 2024, then plunged by 7296.39% to -$51.8 million in 2025, then soared by 155.06% to $28.5 million in 2026.
• Business Quant data shows ASTH's EBIT at $28.5 million in Q1 2026, -$51.8 million in Q4 2025, and $19.2 million in Q3 2025.